Literature DB >> 15647361

A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.

Lino C Gonzalez1, Kelly M Loyet, Jill Calemine-Fenaux, Vandana Chauhan, Bernd Wranik, Wenjun Ouyang, Dan L Eaton.   

Abstract

Immune cell cosignaling receptors are important modulators of immune cell function. For T cells, cosignaling receptors supply necessary secondary signals supporting activation or attenuation after engagement of antigen-presenting cells. The primary cosignaling receptors belong to either the Ig (CD28-like) or TNF receptor (TNFR) superfamilies. The CD28 family is comprised of coinhibitory and costimulatory receptors. The three coinhibitory receptors are cytotoxic T lymphocyte antigen 4, programmed death-1, and B and T lymphocyte attenuator (BTLA). Although cytotoxic T lymphocyte antigen 4 and programmed death-1 interact with B7-Ig family counter receptors, the ligand for BTLA is less clear. From a protein-protein interaction screen, we identified the TNFR family member herpesvirus entry mediator (HVEM) as a counter receptor for BTLA. Here we show that HVEM binds BTLA with high affinity and can form a ternary complex with its known ligands homologous to lymphotoxin, showing inducible expression, and competing with herpes simplex virus glycoprotein D for HVEM, a receptor expressed by T lymphocytes (LIGHT) or lymphotoxin alpha and BTLA. In addition, binding of HVEM to BTLA attenuates T cell activation, identifying HVEM/BTLA as a coinhibitory receptor pair. This study is a demonstration of a direct interaction between the primary T cell cosignaling receptors of the CD28 and TNFR families.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647361      PMCID: PMC544343          DOI: 10.1073/pnas.0409071102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response.

Authors:  K Tamada; K Shimozaki; A I Chapoval; Y Zhai; J Su; S F Chen; S L Hsieh; S Nagata; J Ni; L Chen
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

2.  Localization of the gD-binding region of the human herpes simplex virus receptor, HveA.

Authors:  J C Whitbeck; S A Connolly; S H Willis; W Hou; C Krummenacher; M Ponce de Leon; H Lou; I Baribaud; R J Eisenberg; G H Cohen
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry.

Authors:  J C Whitbeck; C Peng; H Lou; R Xu; S H Willis; M Ponce de Leon; T Peng; A V Nicola; R I Montgomery; M S Warner; A M Soulika; L A Spruce; W T Moore; J D Lambris; P G Spear; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family.

Authors:  R I Montgomery; M S Warner; B J Lum; P G Spear
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

5.  LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator.

Authors:  D N Mauri; R Ebner; R I Montgomery; K D Kochel; T C Cheung; G L Yu; S Ruben; M Murphy; R J Eisenberg; G H Cohen; P G Spear; C F Ware
Journal:  Immunity       Date:  1998-01       Impact factor: 31.745

6.  Inhibition of herpes simplex virus gD and lymphotoxin-alpha binding to HveA by peptide antagonists.

Authors:  M R Sarrias; J C Whitbeck; I Rooney; L Spruce; B K Kay; R I Montgomery; P G Spear; C F Ware; R J Eisenberg; G H Cohen; J D Lambris
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation.

Authors:  B S Kwon; K B Tan; J Ni; K O Oh; Z H Lee; K K Kim; Y J Kim; S Wang; R Gentz; G L Yu; J Harrop; S D Lyn; C Silverman; T G Porter; A Truneh; P R Young
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

8.  Differential T cell costimulatory requirements in CD28-deficient mice.

Authors:  A Shahinian; K Pfeffer; K P Lee; T M Kündig; K Kishihara; A Wakeham; K Kawai; P S Ohashi; C B Thompson; T W Mak
Journal:  Science       Date:  1993-07-30       Impact factor: 47.728

Review 9.  The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

Authors:  James L Riley; Carl H June
Journal:  Blood       Date:  2004-09-07       Impact factor: 22.113

Review 10.  LIGHT-HVEM signaling and the regulation of T cell-mediated immunity.

Authors:  Steve W Granger; Sandra Rickert
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

View more
  98 in total

1.  Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.

Authors:  Lisa Yan; Diane M Da Silva; Bhavna Verma; Andrew Gray; Heike E Brand; Joseph G Skeate; Tania B Porras; Shreya Kanodia; W Martin Kast
Journal:  Prostate       Date:  2014-11-14       Impact factor: 4.104

2.  Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus.

Authors:  M Zhang; K Howard; A Winters; S Steavenson; S Anderson; S Smelt; G Doellgast; C Sheelo; J Stevens; H Kim; A Hamburger; A Sein; D J Caughey; F Lee; H Hsu; G Siu; F R Byrne
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

3.  The LIGHT and DARC sides of herpesvirus entry mediator.

Authors:  Tania H Watts; Jennifer L Gommerman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-13       Impact factor: 11.205

4.  Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway.

Authors:  Timothy C Cheung; Ian R Humphreys; Karen G Potter; Paula S Norris; Heather M Shumway; Bonnie R Tran; Ginelle Patterson; Rochelle Jean-Jacques; Miri Yoon; Patricia G Spear; Kenneth M Murphy; Nell S Lurain; Chris A Benedict; Carl F Ware
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-30       Impact factor: 11.205

Review 5.  The many sounds of T lymphocyte silence.

Authors:  Ignacio Melero; Ainhoa Arina; Lieping Chen
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  Herpesvirus Entry Mediator and Ocular Herpesvirus Infection: More than Meets the Eye.

Authors:  Rebecca G Edwards; Richard Longnecker
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

7.  Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator.

Authors:  Yoshihiro Oya; Norihiko Watanabe; Takayoshi Owada; Mie Oki; Koichi Hirose; Akira Suto; Shin-Ichiro Kagami; Hiroshi Nakajima; Takashi Kishimoto; Itsuo Iwamoto; Theresa L Murphy; Kenneth M Murphy; Yasushi Saito
Journal:  Arthritis Rheum       Date:  2008-08

8.  Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis.

Authors:  Eduardo Huarte; SangMu Jun; Agnieszka Rynda-Apple; Sara Golden; Larissa Jackiw; Carol Hoffman; Massimo Maddaloni; David W Pascual
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

Review 9.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function.

Authors:  Gang Cai; Xiaomeng Nie; Lei Li; Liang Hu; Beiying Wu; Jiafei Lin; Cen Jiang; Huaizhou Wang; Xuefeng Wang; Qian Shen
Journal:  J Gastroenterol       Date:  2013-03-27       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.